Lubos Sobotka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lubos Sobotka has a total of 279 co-authors. Here are the top co-authors by number of shared publications:
- Vladimir Blaha
The 3rd Department of Internal Medicine-Metabolic Care and Gerontology, University Hospital and Faculty of Medicine in Hradec Králové, Charles University, 50005 Hradec Kralove, Czech Republic
31 shared publications - Milan Bláha
4th Department of Internal Medicine-Haematology, Faculty Hospital in Hradec Králové, 50005 Hradec Králové, Czech Republic
14 shared publications - Sylvie Dusilová-Sulková
University Hospital Hradec Kralové, Hemodialysis Centre, Hradec Králové, Czech Republic
14 shared publications - Lenka Kujovská Krčmová
Department of Clinical Biochemistry and Diagnostics , University Hospital Hradec Králové , Hradec Králové , Czech Republic
11 shared publications - Zdeněk Zadák
Department of Clinical Biochemistry and Diagnostics, Faculty of Medicine and University Hospital, Charles University, Sokolska Str. 581, 500 05 Hradec Kralove, Czech Republic
10 shared publications - Marta Kalousová
Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
7 shared publications
Latest Publications
- 1 November 2017
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 30, 159-165
Antioxidant defense system in familial hypercholesterolemia and the effects of lipoprotein apheresis
- 1 November 2017
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 30, 159-165
Antioxidant defense system in familial hypercholesterolemia and the effects of lipoprotein apheresis
- 1 August 2017
- Published by Elsevier in Atherosclerosis
- Vol. 263, e150
LDL Apheresis – long-term follow-up in a Czech centre
- 1 August 2017
- Published by Elsevier in Atherosclerosis
- Vol. 263, e150
LDL Apheresis – long-term follow-up in a Czech centre
- 1 August 2017
- Published by Elsevier in Atherosclerosis
- Vol. 263, e223-e224
Long-term high carbohydrate parenteral nutrition does not have negative effect on the hepatic function and triglyceridemia
- 1 August 2017
- Published by Elsevier in Atherosclerosis
- Vol. 263, e223-e224
Long-term high carbohydrate parenteral nutrition does not have negative effect on the hepatic function and triglyceridemia
- 1 August 2017
- Published by Elsevier in Atherosclerosis
- Vol. 263, e223
Plasma NEFA concentration in ICU patients are not related to the fat/glucose based parenteral nutrition regime
- 1 August 2017
- Published by Elsevier in Atherosclerosis
- Vol. 263, e223
Plasma NEFA concentration in ICU patients are not related to the fat/glucose based parenteral nutrition regime
- 1 August 2017
- Published by Elsevier in Atherosclerosis
- Vol. 263, e244
Impact of lipoprotein apheresis on the content of alpha-tocopherol in cell membranes and lipid peroxidation
- 1 August 2017
- Published by Elsevier in Atherosclerosis
- Vol. 263, e244
Impact of lipoprotein apheresis on the content of alpha-tocopherol in cell membranes and lipid peroxidation
- 1 June 2017
- Published by Elsevier in Clinical Nutrition
- Vol. 36 (3) , 896-901
Defining malnutrition: A plea to rethink
- 1 June 2017
- Published by Elsevier in Clinical Nutrition
- Vol. 36 (3) , 896-901
Defining malnutrition: A plea to rethink
- 15 April 2017
- Published by Institute of Physiology of the Czech Academy of Sciences in Physiological Research
- Vol. 66, S91-S100
Lipoprotein Apheresis in the Treatment of Dyslipidemia – the Czech Republic Experience
In 1984, we started using therapeutic plasmapheresis (plasma exchange) as a method of extracorporeal lipoprotein elimination for the treatment of hypercholesterolemic patients. We evaluated the results of long-term therapy in 14 patients, 8 men and 6 women. The average age was 55.6±13.2 (range 28-70), median 59.5 years. 14 patients were diagnosed with familial hypercholesterolemia (FH): 5 homozygous, 9 heterozygous. Ten patients in the group were treated using immunoadsorption lipoprotein apheresis and 4 using hemorheopheresis. Immunoapheretic interventions decreased LDL-cholesterol (82±1 %), ApoB (73±13 %) and even Lp(a) by 82±19 %, respectively. Selected non-invasive methods are important for long-term and repeated follow-up. Carotid intima-media thickness showed improvement or stagnation in 75 % of the patients. Biomarkers of endothelial dysfunction such as endoglin (in the control group: 3.85±1.25 μg/l, in lipoprotein apheresis-treated hypercholesterolemic individuals 5.74±1.47 μg/l), CD40 ligand (before lipoprotein apheresis: 6498±2529 ng/l, after lipoprotein apheresis: 4057±2560 ng/l) and neopterin (before lipoprotein apheresis: 5.7±1.1 nmol/l, after lipoprotein apheresis: 5.5±1.3 nmol/l) related to the course of atherosclerosis, but did not reflect the actual activity of the disease nor facilitate the prediction or planning of therapy. Hemorheopheresis may improve blood flow in microcirculation in familial hypercholesterolemia and also in some other microcirculation disorders via significantly decreased activity of thrombomodulin (p<0.0001), tissue factor (p<0.0001), aggregation of thrombocytes (p<0.0001) and plasma and whole blood viscosity (p<0.0001). In conclusion, lipoprotein apheresis and hemorheopheresis substantially lowered LDL-cholesterol in severe hypercholesterolemia. Our experience with long-term therapy also shows good tolerance and a small number of complications (6.26 % non-serious clinical complications).
- 15 April 2017
- Published by Institute of Physiology of the Czech Academy of Sciences in Physiological Research
- Vol. 66, S91-S100
Lipoprotein Apheresis in the Treatment of Dyslipidemia – the Czech Republic Experience
In 1984, we started using therapeutic plasmapheresis (plasma exchange) as a method of extracorporeal lipoprotein elimination for the treatment of hypercholesterolemic patients. We evaluated the results of long-term therapy in 14 patients, 8 men and 6 women. The average age was 55.6±13.2 (range 28-70), median 59.5 years. 14 patients were diagnosed with familial hypercholesterolemia (FH): 5 homozygous, 9 heterozygous. Ten patients in the group were treated using immunoadsorption lipoprotein apheresis and 4 using hemorheopheresis. Immunoapheretic interventions decreased LDL-cholesterol (82±1 %), ApoB (73±13 %) and even Lp(a) by 82±19 %, respectively. Selected non-invasive methods are important for long-term and repeated follow-up. Carotid intima-media thickness showed improvement or stagnation in 75 % of the patients. Biomarkers of endothelial dysfunction such as endoglin (in the control group: 3.85±1.25 μg/l, in lipoprotein apheresis-treated hypercholesterolemic individuals 5.74±1.47 μg/l), CD40 ligand (before lipoprotein apheresis: 6498±2529 ng/l, after lipoprotein apheresis: 4057±2560 ng/l) and neopterin (before lipoprotein apheresis: 5.7±1.1 nmol/l, after lipoprotein apheresis: 5.5±1.3 nmol/l) related to the course of atherosclerosis, but did not reflect the actual activity of the disease nor facilitate the prediction or planning of therapy. Hemorheopheresis may improve blood flow in microcirculation in familial hypercholesterolemia and also in some other microcirculation disorders via significantly decreased activity of thrombomodulin (p<0.0001), tissue factor (p<0.0001), aggregation of thrombocytes (p<0.0001) and plasma and whole blood viscosity (p<0.0001). In conclusion, lipoprotein apheresis and hemorheopheresis substantially lowered LDL-cholesterol in severe hypercholesterolemia. Our experience with long-term therapy also shows good tolerance and a small number of complications (6.26 % non-serious clinical complications).